LEISHDNAVAX (visceral leishmaniasis)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2009
  • Initiating Organization: European Commission
  • Initiator Type: Government
  • Disease focus:
    visceral leishmaniasis
  • Location: Europe


This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).


The focus of the EU-funded 'Development of a DNA vaccine for visceral leishmaniasis' (LEISHDNAVAX) project was to deliver a pre-clinical candidate for the development of a prophylactic and therapeutic vaccine. Research over the past few years has shown that immunity against leishmaniasis is mediated by T lymphocytes together with macrophages and dendritic cells. Based on this, LEISHDNAVAX partners designed a vaccine strategy that would mainly trigger the activation of T cells.

Structure & Governance

This consortium is the project of CORDIS (Community Research and Development Information Service), which is a program of the European Commission.


Funded by the European Commission

Data Sharing

Work produced by the consortium is owned by the European Commission


To view the consortium’s final report summary, click here

Points of Contact

Administrative contact: Penny Ireland
Tel.: +44-20-79272678
Fax: +44-20-75805636

Sponsors & Partners

Mologen AG

Charite – Universitaetmedizin Berlin

Council of Scientific and Industrial Research

Institut Pasteur De Tuni

The Hebrew University of Jerusalem

Indian Council of Medical Research

Drugs for Neglected Diseases Initiative Foundation

Last Updated: 06/20/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.